Ainos, Inc. Reports 412% Revenue Growth to $106,207 in Q1 2025

Ainos, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2025. The company generated revenues of $106,207, a substantial increase of 412% compared to $20,729 in the same period last year. This growth was primarily driven by the realization of $105,942 in revenue from sales of VOC sensing products related to a co-development project with Nisshinbo Micro Devices Inc. (NISD). The cost of revenues decreased to $18,233 from $26,754, resulting in a gross profit of $87,974, a notable turnaround from a gross loss of $6,025 in Q1 2024.

Despite the increase in revenue, Ainos reported a net loss of $3,286,022 for the first quarter of 2025, slightly improved from a net loss of $3,314,810 in the prior year. The operating loss was $3,162,871, reflecting a marginal increase of 1% from the previous year. The company’s operating expenses rose to $3,250,845, up from $3,114,066, largely due to increased selling, general, and administrative expenses, which surged by 48% to $1,526,761. Research and development expenses decreased by 17% to $1,724,084, attributed to reduced clinical trial fees and staffing expenditures.

In terms of strategic developments, Ainos has been actively expanding its product portfolio and partnerships. The company has formed a strategic partnership with ugo, Inc., a Japanese service robot developer, to integrate its AI Nose technology into autonomous robotic platforms. This collaboration aims to enhance industrial safety and healthcare applications. Additionally, Ainos has continued to advance its VELDONA product line, which includes therapies targeting various health conditions, and has licensed patents from Taiwan Carbon Nano Technology Corporation to bolster its intellectual property in VOC and point-of-care testing technologies.

Operationally, Ainos reported a decrease in cash and cash equivalents, which stood at $2,628,286 as of March 31, 2025, down from $3,892,919 at the end of 2024. The company utilized $1,224,578 in cash for operating activities during the quarter, a reduction from $1,494,747 in the same period last year. Ainos also engaged in an At The Market Offering Agreement, generating $14,605 in net proceeds from the sale of 29,407 shares of common stock. Looking ahead, Ainos anticipates continued investment in research and development, particularly for its VOC point-of-care testing and VELDONA drug candidates, while acknowledging the need for additional capital to support its operations and growth strategy.